| Bid | n/a |
| Market Cap | 34.17M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.43 |
| PE Ratio (ttm) | -2.36 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | n/a |
| Volume | 27,682 |
| Avg. Volume (20D) | 30,062 |
| Open | 3.43 |
| Previous Close | 3.24 |
| Day's Range | 3.20 - 3.45 |
| 52-Week Range | 1.98 - 3.60 |
| Beta | undefined |
About ACST
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada....
Analyst Forecast
According to 2 analyst ratings, the average rating for ACST stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
7 months ago · investorplace.com
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuat...
3 years ago · newsfilecorp.com
Acasti Pharma To Present At The Q4 Investor Summit on November 16thLaval, Quebec--(Newsfile Corp. - November 11, 2021) - Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST) ("Acasti" or the "Company"), today announced that management will present at the Q4 Investor Summit...
